Some big deals in the second quarter have raised hopes that takeouts are back.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.